# Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

Study · id `cardio:ct-nct05666128` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05666128](<https://clinicaltrials.gov/study/NCT05666128>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05666128

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT05666128. Randomized; double masking; primary purpose treatment. Start 2022-06-17 (actual); primary completion 2023-06-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT05666128, source copy `cardio:ctgov-nct05666128-2024-10-18`, retrieved 2026-10-26)
- Started: 2022-06-17 (actual) (ClinicalTrials.gov record NCT05666128, source copy `cardio:ctgov-nct05666128-2024-10-18`, retrieved 2026-10-26)
- Primary completion: 2023-06-28 (actual) (ClinicalTrials.gov record NCT05666128, source copy `cardio:ctgov-nct05666128-2024-10-18`, retrieved 2026-10-26)
- Completion: 2023-07-28 (actual) (ClinicalTrials.gov record NCT05666128, source copy `cardio:ctgov-nct05666128-2024-10-18`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05666128, source copy `cardio:ctgov-nct05666128-2024-10-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05666128-2024-10-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of HD-6277 in Adult Patients with Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): HD-6277
- Intervention (Drug): HD-6277
- Intervention (Drug): Placebo
- Lead sponsor: Hyundai Pharm
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hyundai Pharm (`cardio:org-hyundai-pharm`)

## Provenance

Content hash: 8e53293d9477fe4ab6c7a33554226290d638e869cfc79a515ac9bfd3a45cd659
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
